Literature DB >> 18683321

Strain-specific spontaneous and NNK-mediated tumorigenesis in Pten+/- mice.

Mary Christine Hollander1, Andria R Balogh, Jaminelli Liwanag, Wei Han, Ritva Ilona Linnoila, Miriam R Anver, Phillip A Dennis.   

Abstract

Pten is a negative regulator of the Akt pathway, and its inactivation is believed to be an etiological factor in many tumor types. Pten+/- mice are susceptible to a variety of spontaneous tumor types, depending on strain background. Pten+/- mice, in lung tumor-sensitive and -resistant background strains, were treated with a tobacco carcinogen, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK), to determine whether allelic Pten deletion can cooperate with NNK in carcinogenesis in lung or other tissues. In lung tumor-resistant C57BL/6 Pten+/- or +/+ mice, NNK treatment did not lead to any lung tumors and did not increase the incidence or severity of tumors previously reported for this strain. In contrast, in a lung tumor-susceptible pseudo-A/J strain, there was a dose-dependent increase in lung tumor size in Pten+/- compared with +/+ mice, although there was no increase in multiplicity. No other tumor types were observed in pseudo-A/J Pten+/- mice regardless of NNK treatment. Lung tumors from these Pten+/- mice had K-ras mutations, retained Pten expression and had similar Akt pathway activation as lung tumors from +/+ mice. Therefore, deletion of a single copy of Pten does not substantially add to the lung tumor phenotype conferred by mutation of K-ras by NNK, and there is likely no selective advantage for loss of the second Pten allele in lung tumor initiation.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18683321      PMCID: PMC2504769          DOI: 10.1593/neo.08406

Source DB:  PubMed          Journal:  Neoplasia        ISSN: 1476-5586            Impact factor:   5.715


  27 in total

1.  Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation.

Authors:  J Brognard; A S Clark; Y Ni; P A Dennis
Journal:  Cancer Res       Date:  2001-05-15       Impact factor: 12.701

2.  Ki-ras activation and expression in transformed mouse lung cell lines.

Authors:  Y H Pan; E O Nuzum; L A Hanson; D G Beer
Journal:  Mol Carcinog       Date:  1990       Impact factor: 4.784

3.  Phosphorylated Akt overexpression and loss of PTEN expression in non-small cell lung cancer confers poor prognosis.

Authors:  Jian-Min Tang; Quan-Ying He; Rui-Xia Guo; Xiu-Jun Chang
Journal:  Lung Cancer       Date:  2006-02       Impact factor: 5.705

4.  Binding of ras to phosphoinositide 3-kinase p110alpha is required for ras-driven tumorigenesis in mice.

Authors:  Surbhi Gupta; Antoine R Ramjaun; Paula Haiko; Yihua Wang; Patricia H Warne; Barbara Nicke; Emma Nye; Gordon Stamp; Kari Alitalo; Julian Downward
Journal:  Cell       Date:  2007-06-01       Impact factor: 41.582

5.  Role of the alveolar type II cell in the development and progression of pulmonary tumors induced by 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone in the A/J mouse.

Authors:  S A Belinsky; T R Devereux; J F Foley; R R Maronpot; M W Anderson
Journal:  Cancer Res       Date:  1992-06-01       Impact factor: 12.701

6.  PTEN expression in non-small-cell lung cancer: evaluating its relation to tumor characteristics, allelic loss, and epigenetic alteration.

Authors:  Carmen J Marsit; Shichun Zheng; Kenneth Aldape; Philip W Hinds; Heather H Nelson; John K Wiencke; Karl T Kelsey
Journal:  Hum Pathol       Date:  2005-07       Impact factor: 3.466

7.  Additional evidence that the K-ras protooncogene is a candidate for the major mouse pulmonary adenoma susceptibility (Pas-1) gene.

Authors:  L Lin; M F Festing; T R Devereux; K A Crist; S C Christiansen; Y Wang; A Yang; K Svenson; B Paigen; A M Malkinson; M You
Journal:  Exp Lung Res       Date:  1998 Jul-Aug       Impact factor: 2.459

8.  Pten controls lung morphogenesis, bronchioalveolar stem cells, and onset of lung adenocarcinomas in mice.

Authors:  Shigehisa Yanagi; Hiroyuki Kishimoto; Kohichi Kawahara; Takehiko Sasaki; Masato Sasaki; Miki Nishio; Nobuyuki Yajima; Koichi Hamada; Yasuo Horie; Hiroshi Kubo; Jeffrey A Whitsett; Tak Wah Mak; Toru Nakano; Masamitsu Nakazato; Akira Suzuki
Journal:  J Clin Invest       Date:  2007-10       Impact factor: 14.808

Review 9.  PTEN hamartomatous tumor syndromes (PHTS): rare syndromes with great relevance to common cancers and targeted drug development.

Authors:  Jaclyn Lopiccolo; Marc S Ballas; Phillip A Dennis
Journal:  Crit Rev Oncol Hematol       Date:  2007-07-20       Impact factor: 6.312

10.  Tobacco-specific nitrosamines: formation from nicotine in vitro and during tobacco curing and carcinogenicity in strain A mice.

Authors:  S S Hecht; C B Chen; N Hirota; R M Ornaf; T C Tso; D Hoffmann
Journal:  J Natl Cancer Inst       Date:  1978-04       Impact factor: 13.506

View more
  14 in total

1.  Dinosaurs and ancient civilizations: reflections on the treatment of cancer.

Authors:  Alnawaz Rehemtulla
Journal:  Neoplasia       Date:  2010-12       Impact factor: 5.715

2.  A Cyp2a polymorphism predicts susceptibility to NNK-induced lung tumorigenesis in mice.

Authors:  M Christine Hollander; Xin Zhou; Colleen R Maier; Andrew D Patterson; Xinxin Ding; Phillip A Dennis
Journal:  Carcinogenesis       Date:  2011-05-30       Impact factor: 4.944

3.  Development of Kras mutant lung adenocarcinoma in mice with knockout of the airway lineage-specific gene Gprc5a.

Authors:  Junya Fujimoto; Sayuri Nunomura-Nakamura; Yihua Liu; Wenhua Lang; Tina McDowell; Yasminka Jakubek; Dalia Ezzeddine; Joshua Kapere Ochieng; Jason Petersen; Gareth Davies; Junya Fukuoka; Ignacio I Wistuba; Erik Ehli; Jerry Fowler; Paul Scheet; Humam Kadara
Journal:  Int J Cancer       Date:  2017-07-17       Impact factor: 7.396

4.  The tobacco carcinogen nitrosamine induces a differential gene expression response in tumour susceptible A/J and resistant C3H mouse lungs.

Authors:  William Gordon; Valentin Galitovskiy; Robert Edwards; Bogi Andersen; Sergei A Grando
Journal:  Eur J Cancer       Date:  2012-09-23       Impact factor: 9.162

Review 5.  PTEN loss in the continuum of common cancers, rare syndromes and mouse models.

Authors:  M Christine Hollander; Gideon M Blumenthal; Phillip A Dennis
Journal:  Nat Rev Cancer       Date:  2011-04       Impact factor: 60.716

6.  The War on Cancer rages on.

Authors:  Alnawaz Rehemtulla
Journal:  Neoplasia       Date:  2009-12       Impact factor: 5.715

7.  Comparative functional genomics analysis of NNK tobacco-carcinogen induced lung adenocarcinoma development in Gprc5a-knockout mice.

Authors:  Junya Fujimoto; Humam Kadara; Taoyan Men; Carolyn van Pelt; Dafna Lotan; Reuben Lotan
Journal:  PLoS One       Date:  2010-07-29       Impact factor: 3.240

8.  Neoplasia: the second decade.

Authors:  Alnawaz Rehemtulla
Journal:  Neoplasia       Date:  2008-12       Impact factor: 5.715

9.  Suppression of antifolate resistance by targeting the myosin Va trafficking pathway in melanoma.

Authors:  María Piedad Fernández-Pérez; María F Montenegro; Magalí Sáez-Ayala; Luis Sánchez-del-Campo; Antonio Piñero-Madrona; Juan Cabezas-Herrera; José Neptuno Rodríguez-López
Journal:  Neoplasia       Date:  2013-07       Impact factor: 5.715

10.  Human melanoma cells under endoplasmic reticulum stress acquire resistance to microtubule-targeting drugs through XBP-1-mediated activation of Akt.

Authors:  Chen Chen Jiang; Fan Yang; Rick F Thorne; Bi Ke Zhu; Peter Hersey; Xu Dong Zhang
Journal:  Neoplasia       Date:  2009-05       Impact factor: 5.715

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.